City of Hope was awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) within the US Department of Health and Human Services. The grant will help City of Hope create a bio map of tumor changes that cause immunotherapy resistance in advanced or metastatic non-small cell lung cancer. Press release.

Yseop announced the next phase in delivering its One-Click Dossier vision, a scalable automation approach designed to streamline regulatory document generation and reduce time-to-submission. The One-Click Dossier streamlines the production of high quality regulatory documents, such as Clinical Study Reports (CSRs), patient narratives, summaries, and others in a fully automated workflow. By eliminating manual steps from data ingestion to draft creation, Yseop empowers life sciences teams to generate compliant, submission ready documents with significantly less effort and greater accuracy. Press release.

Veeva and Sarah Cannon Research Institute (SCRI) announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting Veeva Clinical Platform to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites, improving how investigators and clinical teams work together and share data. With a connected foundation for clinical research, SCRI will be able to automate key processes and provide a streamlined experience for its sites. Press release.

Veeva has also entered a strategic partnership with Accumulus that is focused on enabling connectivity to help the life sciences industry more effectively exchange regulated information with national regulatory authorities (NRAs) around the world. The partnership is designed to bridge current requirements and emerging needs, supporting near-term connectivity while aligning with global efforts to modernize regulatory technology. It aims to enable life sciences organizations to seamlessly connect systems across borders and platforms without being locked into legacy approaches. Press release.

Oracle has made new interoperability advancements the company’s Randomization and Trial Supply Management (RTSM) solution, which are helping simplify and optimize drug supply management across complex clinical trials and multiple therapeutic areas. New drug pooling and interoperability enhancements enable sponsors and CROs to control drug inventory across various clinical trials simultaneously using the same investigational product. This aids in reducing inefficiencies and waste, as well as accelerating trial execution timelines. In addition, Oracle RTSM now supports fully integrated supply management with SAP, Almac, Fisher Clinical Services, Catalent, and PMD to help the right drug reach the right site at the right time, regardless of the study’s technology platform. Press re

Labcorp announced the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma solutions designed to accelerate clinical trials and companion diagnostic development. Some developments include: the availability of new NGS panels for myeloid, lymphoid, and pan-heme indications, expansion of capabilities of OmniSeq INSIGHT, expanded FDA-approved companion diagnostics, and more. Press release.

Seer and Korea University announced the launch of a population-level study aimed at identifying novel blood-based biomarkers that could lead to cancer diagnostics for young adults in their 20s and 30s. Using Seer’s newly launched Proteograph ONE Assay and SP200 Automation Instrument along with the Thermo Scientific Orbitrap Astral mass spectrometer, this is the first large-scale plasma proteomics initiative of its kind to leverage mass spectrometry and AI-driven analytics to enhance early cancer detection and improve patient outcomes. Press release.

Clinigen reached a key collaborative milestone with Shionogi, launching their new strategic relationship. Clinigen CEO Jerome Charton met with Shionogi President and CEO Dr. Isao Teshirogi at the Shionogi global headquarters in Osaka, Japan, for a ceremonial signing event to mark the progress following the exclusive licensing agreement for cefiderocol, which was announced by Shionogi in April. Under the terms of the agreement, Clinigen will in-license cefiderocol from Shionogi and obtain exclusive rights for its development and commercialization in Australia and New Zealand. Shionogi will receive an upfront payment, milestone payments based on development progress, and royalties from Clinigen. Press release.

Medable unveiled its digital-first Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials. Medable’s platform reduces the burden on patients and sites involved in complex CGT trials and enhances scientific integrity with sustainable data capture across the FDA-required 15-year follow-up period for certain CGTs, including those using genome-editing techniques like CRISPR-Cas9. This extended monitoring period is essential for tracking delayed adverse events, understanding the durability of the therapy, and ensuring the long-term impact on patients, but can add significant hardships. Features include: remote and hybrid patient interaction, personalized patient communication, and more. Press release.